Cellectis (NASDAQ:CLLS – Get Free Report) and Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.
Volatility and Risk
Cellectis has a beta of 3.1, suggesting that its share price is 210% more volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 2.6, suggesting that its share price is 160% more volatile than the S&P 500.
Institutional & Insider Ownership
63.9% of Cellectis shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 9.2% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cellectis | $29.07 million | 3.58 | -$101.06 million | ($1.30) | -1.44 |
| Tectonic Therapeutic | N/A | N/A | $12.16 million | ($5.89) | -6.87 |
Tectonic Therapeutic has lower revenue, but higher earnings than Cellectis. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Cellectis and Tectonic Therapeutic, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cellectis | 0 | 0 | 3 | 0 | 3.00 |
| Tectonic Therapeutic | 0 | 0 | 4 | 1 | 3.20 |
Cellectis currently has a consensus target price of $7.00, indicating a potential upside of 274.33%. Tectonic Therapeutic has a consensus target price of $74.67, indicating a potential upside of 84.59%. Given Cellectis’ higher probable upside, analysts clearly believe Cellectis is more favorable than Tectonic Therapeutic.
Profitability
This table compares Cellectis and Tectonic Therapeutic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cellectis | -234.39% | -74.55% | -22.65% |
| Tectonic Therapeutic | N/A | -35.53% | -31.97% |
Summary
Cellectis beats Tectonic Therapeutic on 8 of the 14 factors compared between the two stocks.
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
About Tectonic Therapeutic
Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.
